Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Recently, it has reported that mCAPIRI is well tolerated and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int J Clin Oncol
Hauptverfasser: Suzuki, Nobuaki, Hazama, Shoichi, Nagasaka, Takeshi, Tanioka, Hiroaki, Iwamoto, Yasuo, Negoro, Yuji, Yamauchi, Masami, Kobayashi, Michiya, Okuda, Hiroshi, Fujishima, Noriaki, Nishimura, Taku, Yamanaka, Naoki, Toyota, Kazuhiro, Mori, Yoshiko, Nakagami, Yuki, Shimokawa, Mototsugu, Nagano, Hiroaki, Okajima, Masazumi
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Singapore 2019
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736909/
https://ncbi.nlm.nih.gov/pubmed/31144145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-019-01473-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge